BioCentury
ARTICLE | Company News

Cell Therapeutics, Teva deal

December 9, 2013 8:00 AM UTC

Cell Therapeutics received a $5 million milestone payment from Teva under a 2005 deal in which Cephalon Inc. acquired Cell Therapeutics' Trisenox arsenic trioxide for acute promyelocytic leukemia. ...